By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) > Dostarlimab
Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Dostarlimab

https://themeditary.com/drug/dostarlimab-6701.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 14, 2023  Additional Content by TheMediTary.Com

Generic name: dostarlimab [ dos-tar-li-mab ]

Drug class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Dosage form: intravenous solution (gxly 500 mg/10 ml)

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Jemperli

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Dostarlimab?

Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed by surgery.

Your doctor will make sure you have the correct tumor type to be treated with dostarlimab.

Dostarlimab may also be used for purposes not listed in this medication guide.

Warnings

Call your doctor at once if you have new or worsening symptoms such as: cough, chest pain, breathing problems, severe stomach pain, diarrhea, bloody or tarry stools, headaches, confusion, severe weakness, vision problems, decreased urination, bruising or bleeding, blood in your urine, dark urine, or yellowing of the skin or eyes.

How should I take Dostarlimab

Dostarlimab is injected into a vein by a healthcare provider. This medicine is injected slowly over 30 minutes.

Dostarlimab is usually given every 3 weeks at first, and then every 6 weeks.

You may need medical tests to help determine how long you should use dostarlimab.

Dosing information

Usual Adult Dose for Endometrial Carcinoma:

Initial dose:
-Dose 1 through Dose 4: 500 mg IV over 30 minutes every 3 weeks
Maintenance dose:
-Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg IV over 30 minutes every 6 weeks
Duration of therapy:
-Until disease progression or unacceptable toxicity

Use: For the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an approved test, that has progressed on or following prior treatment with a platinum-containing regimen and are not candidates for curative surgery or radiation

Usual Adult Dose for Solid Tumors:

Initial dose:
-Dose 1 through Dose 4: 500 mg IV over 30 minutes every 3 weeks
Maintenance dose:
-Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg IV over 30 minutes every 6 weeks
Duration of therapy:
-Until disease progression or unacceptable toxicity

Comment:
-This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use: For the treatment of solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options

Detailed Dostarlimab dosage information
Dostarlimab Dosage information (more detail)

Before Taking

Tell your doctor if you have ever had:

  • breathing problems; or

  • immune system problems.

May harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use birth control while using dostarlimab and for at least 4 months after your last dose. Tell your doctor if you become pregnant.

Do not breastfeed while using dostarlimab, and for at least 4 months after your last dose.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your dostarlimab injection.

What happens if I overdose?

Since dostarlimab is given in a medical setting, an overdose is unlikely.

What should I avoid while using Dostarlimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Dostarlimab side effects

Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Some side effects may occur during the injection. Tell your caregiver if you feel light-headed, chilled or feverish, itchy, or short of breath.

Dostarlimab strengthens your immune system to help it attack cancer cells, but it may also attack healthy cells and you could develop serious or fatal side effects.

Dostarlimab may cause serious side effects. Call your doctor at once if you have:

  • new or worsening cough, shortness of breath;

  • chest pain, irregular heartbeats;

  • a light-headed feeling, like you might pass out;

  • a seizure;

  • confusion, hallucinations, eye pain or redness, vision problems;

  • severe stomach pain, nausea, vomiting, diarrhea, bloody or tarry stools;

  • low red blood cells (anemia)--pale skin, tiredness, cold hands and feet;

  • low white blood cell counts--fever, mouth sores, skin sores, sore throat, cough;

  • kidney problems--swelling in your ankles, blood in your urine, little or no urination;

  • liver problems--right-sided upper stomach pain, loss of appetite, bruising or bleeding, dark urine, jaundice (yellowing of the skin or eyes); or

  • signs of a hormonal disorder--frequent or unusual headaches, dizziness, feeling very weak, mood or behavior changes, hoarse or deepened voice, increased hunger or thirst, increased urination, constipation, hair loss, sweating, feeling cold, weight gain or loss.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of dostarlimab may include:

  • abnormal liver function tests;

  • nausea, diarrhea, constipation;

  • low white blood cell counts, anemia; or

  • feeling weak or tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See more: Dostarlimab Side Effects

What other drugs will affect Dostarlimab?

Other drugs may affect dostarlimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

More about Dostarlimab (Dostarlimab [ dos-tar-li-mab ])

Dosage information
Dostarlimab Side Effects
During pregnancy
Drug images
Side effects
Breastfeeding Warnings
Drug class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Related treatment guides

Solid Tumors
Endometrial Cancer
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by